Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients

Journal of Neuro-Oncology

Volumn 76, Issue 1, 2006, Pages 85-92

  Chen, Johnson ^a   Balmaceda, Casilda ^b   Bruce, Jeffrey N ^c   Sisti, Michael B ^c   Huang, May ^b   Cheung, Ying Kuen K ^d   McKhann, Guy M ^c   Goodman, Robert R ^c   Fine, Robert L ^a  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NEUROLOGICAL INSTITUTE   (United States)

^d NONE   (United States)

Author keywords

Brain neoplasms; Cerebrospinal fluid; Drug resistance; P glycoprotein; Tamoxifen

Indexed keywords

GLYCOPROTEIN P; PACLITAXEL; TAMOXIFEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BLOOD SAMPLING; BLOOD TOXICITY; BRAIN CANCER; CEREBELLAR ATAXIA; CEREBROSPINAL FLUID ANALYSIS; CHOROID PLEXUS; CLINICAL ARTICLE; CLINICAL TRIAL; COLUMN CHROMATOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM CELL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METASTASIS POTENTIAL; MONOTHERAPY; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PACLITAXEL; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 30944456274     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-4171-7     Document Type: Article

References (24)

1. C Cordon-Cardo JP O'Brien D Casals L Rittman-Grauer JL Biedler MR Melamed JR Bertino 1989 Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites Proc Natl Acad Sci USA 86 695 2563168 1:CAS:528:DyaL1MXovVWnsw%3D%3D
2. VV Rao JL Dahlheimer ME Bardgett AZ Snyder RA Finch AC Sartorelli D Piwnica-Worms 1999 Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier Proc Natl Acad Sci USA 96 3900 10097135 1:CAS:528:DyaK1MXjslChsLo%3D
3. E Berman M Adams R Duigou-Osterndorf L Godfrey B Clarkson M Andreeff 1991 Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype Blood 77 818 1993221 1:CAS:528:DyaK3MXhslOqtbo%3D
4. RL Fine CW Sachs ME Albers A Safa US Rao G Scarborough J Burchette C Jordan DL Trump 1993 Tamoxifen inhibition of MDR: Laboratory to clinical studies Miyazaki (ed) The Mechanism and New Approach on Drug Resistance of Cancer Cells Elsevier Amsterdam 323-332
5. AR Safa S Roberts M Agresti RL Fine 1994 Tamoxifen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells Biochem Biophys Res Commun 202 606 7913604 10.1006/bbrc.1994.1971 1:CAS:528:DyaK2cXkvF2ht7Y%3D
6. US Rao RL Fine GA Scarborough 1994 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein Biochem Pharmacol 48 287 7914405 10.1016/0006-2952(94)90099-X 1:CAS:528:DyaK2cXlt1Gmurw%3D
7. DL Trump DC Smith PG Ellis MP Rogers SC Schold EP Winer TJ Panella VC Jordan RL Fine 1992 High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine J Natl Cancer Inst 84 1811 1359155 1:STN:280:ByyD2MbkslA%3D
8. MR Fetell SA Grossman JD Fisher B Erlanger E Rowinsky J Stockel 1997 Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium J Clin Oncol 15 3121 9294475 1:CAS:528:DyaK2sXmt1Sqtrs%3D
9. JC Vergniol R Bruno G Montay A Frydman 1992 Determination of taxotere in human plasma by a semi-automated high-performance liquid chromatographic method J Chromatogr 582 273 1362729 1:CAS:528:DyaK3sXhsFI%3D
10. LK Webster NA Crinis KH Stokes JF Bishop 1991 High-performance liquid chromatographic method for the determination of toremifene and its major human metabolites J Chromatogr 565 482 1831461 1:CAS:528:DyaK3MXksVWit7c%3D
11. MJ Glantz H Choy CM Kearns PC Mills LU Wahlberg EG Zuhowski P Calabresi MJ Egorin 1995 Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors J Natl Cancer Inst 87 1077 7616600 1:CAS:528:DyaK2MXnt12nur0%3D
12. KP O'Boyle Y Wang EL Schwartz DL Regl A Einzig JP Dutcher PH Wiernik SB Horwitz 1997 Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids Cancer 79 1022 9041166 1:CAS:528:DyaK2sXhvVehsrg%3D
13. SH Tseng MS Bobola MS Berger JR Silber 1999 Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines Neuro-Oncology 1 101 11550305 1:STN:280:DC%2BD3MrgtFCkug%3D%3D
14. J Ducharme K Fried G Shenouda B Leyland-Jones IW Wainer 1997 Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen Br J Clin Pharmacol 43 189 9131952 10.1046/ j.1365-2125.1997.05029.x 1:CAS:528:DyaK2sXhvFClu7g%3D
15. AL Cheng SE Chuang RL Fine KH Yeh CM Liao JD Lay DS Chen 1998 Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen Biochem Pharmacol 55 523 9514088 10.1016/ S0006-2952(97)00594-7 1:CAS:528:DyaK1cXmsV2jsQ%3D%3D
16. AL Cheng KH Yeh RL Fine SE Chuang CH Yang LH Wang DS Chen 1998 Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma Hepatogastroenterology 45 1955 9951847 1:STN:280:DyaK1M7jsFeiug%3D%3D
17. EA Lien K Wester PE Lonning E Solheim PM Ueland 1991 Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients Br J Cancer 63 641 2021551 1:STN:280:By6B3MvotlA%3D
18. M Vulpen van HB Kal MJ Taphoorn SY El-Sharouni 2002 Changes in blood-brain barrier permeability induced by radiotherapy: Implications for timing of chemotherapy? (Review) Oncol Rep 9 683 12066192
19. SM Chang JG Kuhn J Rizzo HI Robins SC Schold Jr. AM Spence MS Berger M Mehta IF Pollack C Rankin MD Prados 1998 Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report J Clin Oncol 16 2188 9626220 1:CAS:528:DyaK1cXktV2isbY%3D
20. BL Lum S Kaubisch AM Yahanda KM Adler L Jew MN Ehsan NA Brophy J Halsey MP Gosland BI Sikic 1992 Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance J Clin Oncol 10 1635 1403041 1:STN:280:ByyD3MbktFM%3D
21. R Advani HI Saba MS Tallman JM Rowe PH Wiernik J Ramek K Dugan B Lum J Villena E Davis E Paietta M Litchman BI Sikic PL Greenberg 1999 Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar) Blood 93 787 9920827 1:CAS:528:DyaK1MXpsFyjsg%3D%3D
22. EK Rowinsky L Smith YM Wang P Chaturvedi M Villalona E Campbell C Aylesworth SG Eckhardt L Hammond M Kraynak R. Drengler J Stephenson Jr MW Harding DD VonHoff 1998 Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP J Clin Oncol 16 2964 9738565 1:CAS:528:DyaK1cXmtFSls7g%3D
23. WT Couldwell DR Hinton AA Surnock CM DeGiorgio LP Weiner ML Apuzzo L Masri RE Law MH Weiss 1996 Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen Clin Cancer Res 2 619 9816211 1:CAS:528:DyaK28Xis1Wltb8%3D
24. MC Chamberlain PA Kormanik 1995 Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas Arch Neurol 56 703